Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 3933)

## VOLUNTARY ANNOUNCEMENT ACQUISITION OF AWARD SHARES

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

Reference is made to the announcement of the Company dated 13 November 2023 (the "Announcement") in relation to grant a total of 12,096,900 Award Shares to the Grantees in accordance with the terms of the 2023 Share Award Scheme. Unless otherwise defined herein, capitalised terms used herein shall have the same meaning as those defined in the Announcement.

As of today, 3,700,000 Award Shares have been acquired by the Trustee through on-market transactions at prices ranging from HK\$10.04 to HK\$11.20 per share to meet the vesting obligation to the Grantees on 13 November 2024.

The Trustee will, subject to market conditions, continue to purchase from the market the relevant number of the Award Shares, and shall hold the shares on trust for the relevant Grantees until they are vested in such Grantees and delivered in accordance with the terms of the 2023 Share Award Scheme.

## By Order of the Board **The United Laboratories International Holdings Limited Tsoi Hoi Shan** *Chairman*

Hong Kong, 7 November 2024

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.